Eli Lilly's Strategy Pays Off: A New Era for Diabetes and Weight-Loss Treatments

Eli Lilly has raised its profit and revenue forecasts significantly for 2026, driven by strong sales of its GLP-1 weight-loss and diabetes drugs, despite pricing pressures. The company's new drug, Foundayo, is launching well, although it faces competition from Novo's Wegovy. Strong international sales bolster revenue growth.

Eli Lilly has increased its profit and revenue forecasts for 2026, spurred by substantial demand for its GLP-1 diabetes and weight-loss medications. Despite the challenges of declining prices, the pharmaceutical giant's shares rose over 6% as investors show interest in the firm's robust sales performance.

In the first quarter, Lilly outperformed Wall Street expectations by reporting an adjusted profit of $8.55 per share, surpassing the anticipated $6.66. The company forecasts adjusted earnings between $35.50 and $37.00 per share, above prior estimates and anticipates revenues to rise to $82 billion to $85 billion.

Lilly continues to thrive internationally with products like Mounjaro and Zepbound, a trend that propelled the company past its competitors in the global market. Its new weight-loss drug, Foundayo, is entering the U.S. market and serves as a critical test for gaining market share against rivals like Novo's Wegovy.